Fosfomycin Treatment for ESBL E. coli UTI
For uncomplicated cystitis caused by ESBL-producing E. coli susceptible to fosfomycin, treat with a single 3-gram oral dose of fosfomycin trometamol 1. This represents the FDA-approved regimen and is supported by multiple international guidelines as first-line therapy 2, 3.
Treatment Regimen Based on Infection Type
Uncomplicated Cystitis (Lower UTI)
- Dose: Fosfomycin trometamol 3 grams orally as a single dose 1
- Administration: Mix granules with water; may be taken with or without food 1
- Expected outcomes:
The single-dose regimen is particularly advantageous for ESBL infections because fosfomycin maintains excellent in vitro activity (97% susceptibility) against ESBL-producing E. coli 7, 6 and causes minimal collateral damage to normal flora 4.
Complicated UTI or Step-Down Therapy
If this represents a complicated UTI (not simple cystitis), the approach differs:
- Oral step-down after IV therapy: Fosfomycin 3 grams orally once daily for the remaining treatment duration 8, 9
- Total duration: Complete 7-10 days total antibiotic therapy (including initial IV therapy) 8, 9
- A recent 2026 RCT demonstrated that oral fosfomycin transition therapy was non-inferior to continued IV carbapenem/beta-lactam therapy for complicated ESBL UTIs, with 92.8% clinical cure rates 8
For outpatient step-down therapy, common regimens include fosfomycin 3g every 48-72 hours 9, though the 2026 trial used daily dosing with excellent results 8.
Critical Caveats
Fosfomycin is NOT indicated for pyelonephritis or perinephric abscess 1. The FDA label explicitly restricts use to uncomplicated cystitis in women. While IV fosfomycin has been studied for complicated UTI with pyelonephritis in Europe 10, oral fosfomycin lacks strong evidence for upper tract infections 11.
When NOT to Use Single-Dose Fosfomycin:
- Upper UTI symptoms (fever, flank pain, systemic toxicity)
- Male patients (FDA approval limited to women for uncomplicated cystitis) 1
- Suspected pyelonephritis
- Septic shock or severe sepsis
For these scenarios, use IV therapy with ceftriaxone, carbapenem, or ceftazidime-avibactam depending on severity and local resistance patterns 2, 12.
Monitoring and Follow-Up
- No routine post-treatment culture needed if symptoms resolve 2
- Obtain repeat culture if symptoms persist or recur within 2-4 weeks 2
- If bacteriuria persists after fosfomycin, select alternative agents as fosfomycin should not be repeated 1
Resistance Considerations
While fosfomycin shows excellent activity against ESBL E. coli (96.8% susceptibility) 6, resistance is emerging globally through fosA3 gene transmission 13, 14. Current resistance rates remain low at approximately 9.5% among UPEC isolates 15, 14, supporting empirical use when susceptibility is confirmed.
Important: Fosfomycin has inferior bacterial eradication rates compared to nitrofurantoin or TMP-SMX (though clinical cure rates are comparable) 4. However, for ESBL organisms where other oral options are limited, fosfomycin represents one of the few effective oral alternatives 4, 7.